280 related articles for article (PubMed ID: 33140519)
41. Naloxone accessibility without an outside prescription from U.S. community pharmacies: A systematic review.
Lai RK; Friedson KE; Reveles KR; Bhakta K; Gonzales G; Hill LG; Evoy KE
J Am Pharm Assoc (2003); 2022; 62(6):1725-1740. PubMed ID: 35989151
[TBL] [Abstract][Full Text] [Related]
42. Naloxone Accessibility by Standing Order in North Carolina Community Pharmacies.
Marley G; Annis IE; Ostrach B; Egan K; Delamater PL; Bell R; Dasgupta N; Carpenter DM
J Am Pharm Assoc (2003); 2024; 64(3):102021. PubMed ID: 38307248
[TBL] [Abstract][Full Text] [Related]
43. Buprenorphine alone or with naloxone: Which is safer?
Kelty E; Cumming C; Troeung L; Hulse G
J Psychopharmacol; 2018 Mar; 32(3):344-352. PubMed ID: 29433352
[TBL] [Abstract][Full Text] [Related]
44. Trajectory classes of opioid use among individuals in a randomized controlled trial comparing extended-release naltrexone and buprenorphine-naloxone.
Ruglass LM; Scodes J; Pavlicova M; Campbell ANC; Fitzpatrick S; Barbosa-Leiker C; Burlew K; Greenfield SF; Rotrosen J; Nunes EV
Drug Alcohol Depend; 2019 Dec; 205():107649. PubMed ID: 31704382
[TBL] [Abstract][Full Text] [Related]
45. Improved quality of life for opioid-dependent patients receiving buprenorphine treatment in HIV clinics.
Korthuis PT; Tozzi MJ; Nandi V; Fiellin DA; Weiss L; Egan JE; Botsko M; Acosta A; Gourevitch MN; Hersh D; Hsu J; Boverman J; Altice FL;
J Acquir Immune Defic Syndr; 2011 Mar; 56 Suppl 1(Suppl 1):S39-45. PubMed ID: 21317593
[TBL] [Abstract][Full Text] [Related]
46. Therapeutic Drug Monitoring in Buprenorphine/Naloxone Treatment for Opioid Use Disorder: Clinical Feasibility and Optimizing Assay Precision.
Elarabi HF; Hasan N; Marsden J; Radwan D; Adem A; Almamari S; Elrasheed A
Pharmacopsychiatry; 2020 Apr; 53(3):115-121. PubMed ID: 32000269
[TBL] [Abstract][Full Text] [Related]
47. Pharmacist counseling when dispensing naloxone by standing order: A secret shopper study of 4 chain pharmacies.
Contreras J; Baus C; Brandt C; Witry M; Peters J; Evoy KE
J Am Pharm Assoc (2003); 2021; 61(2):e94-e99. PubMed ID: 33153912
[TBL] [Abstract][Full Text] [Related]
48. Point-of-sale Naloxone: Novel Community-based Research to Identify Naloxone Availability.
Olives T; Willhite LA; Lee SC; Evans DK; Jensen A; Regelman HT; McGillis ES
West J Emerg Med; 2020 Aug; 21(5):1188-1194. PubMed ID: 32970574
[TBL] [Abstract][Full Text] [Related]
49. Naloxone availability in independent community pharmacies in Georgia, 2019.
Gilbert L; Elliott J; Beasley L; Oranu E; Roth K; Nguyễn J
Subst Abuse Treat Prev Policy; 2021 Aug; 16(1):63. PubMed ID: 34419089
[TBL] [Abstract][Full Text] [Related]
50. Cost-effectiveness of extended buprenorphine-naloxone treatment for opioid-dependent youth: data from a randomized trial.
Polsky D; Glick HA; Yang J; Subramaniam GA; Poole SA; Woody GE
Addiction; 2010 Sep; 105(9):1616-24. PubMed ID: 20626379
[TBL] [Abstract][Full Text] [Related]
51. Barriers to Buprenorphine Dispensing by Medicaid-Participating Community Retail Pharmacies.
Freeman PR; Hammerslag LR; Ahrens KA; Sharbaugh M; Gordon AJ; Austin AE; Donohue JM; Allen LD; Barnes AJ; Talbert JC
JAMA Health Forum; 2024 May; 5(5):e241077. PubMed ID: 38758569
[TBL] [Abstract][Full Text] [Related]
52. Pharmacist furnishing of naloxone in California: A follow-up analysis.
Puzantian T; Gasper JJ; Ramirez CM
J Am Pharm Assoc (2003); 2021; 61(5):e108-e112. PubMed ID: 34246575
[TBL] [Abstract][Full Text] [Related]
53. First insights into community pharmacy based buprenorphine-naloxone dispensing in Finland.
Uosukainen H; Bell JS; Laitinen K; Tacke U; Ilomäki J; Turunen JH
Int J Drug Policy; 2013 Sep; 24(5):492-7. PubMed ID: 23567099
[TBL] [Abstract][Full Text] [Related]
54. Availability of medications for opioid use disorder in outpatient and inpatient pharmacies in South Florida: a secret shopper survey.
Syros A; Rodriguez MG; Rennick AC; Dima GA; Gibstein AR; de la Parte L; Hermenau MG; Ciraldo KJ; Chueng TA; Tookes HE; Bartholomew TS; Serota DP
Addict Sci Clin Pract; 2022 Nov; 17(1):63. PubMed ID: 36401298
[TBL] [Abstract][Full Text] [Related]
55. Cost Analysis of Buprenorphine Extended-Release Injection Versus Sublingual Buprenorphine/Naloxone Tablets in a Correctional Setting.
Wong JSH; Masson S; Huang A; Romm D; Fong M; Porter T; Sharifi N; Azar P; Mathew N
J Correct Health Care; 2022 Dec; 28(6):368-371. PubMed ID: 36342953
[TBL] [Abstract][Full Text] [Related]
56. Pharmacists' readiness to provide naloxone in community pharmacies in West Virginia.
Thornton JD; Lyvers E; Scott VGG; Dwibedi N
J Am Pharm Assoc (2003); 2017; 57(2S):S12-S18.e4. PubMed ID: 28163027
[TBL] [Abstract][Full Text] [Related]
57. Factors associated with frequent buprenorphine / naloxone initiation in a national survey of Canadian emergency physicians.
MacKinnon N; Lane D; Scheuermeyer F; Kaczorowski J; Dong K; Orkin AM; Daoust R; Moe J; Andolfatto G; Klaiman M; Yan J; Koh JJ; Crowder K; Atkinson P; Savage D; Stempien J; Besserer F; Wale J; Kestler A
PLoS One; 2024; 19(2):e0297084. PubMed ID: 38315732
[TBL] [Abstract][Full Text] [Related]
58. Assessment of naloxone availability in Georgia community pharmacies.
Stone RH; Hur S; Young HN
J Am Pharm Assoc (2003); 2020; 60(2):357-361. PubMed ID: 31866387
[TBL] [Abstract][Full Text] [Related]
59. Expanding substance use treatment options for HIV prevention with buprenorphine-naloxone: HIV Prevention Trials Network 058.
Metzger DS; Donnell D; Celentano DD; Jackson JB; Shao Y; Aramrattana A; Wei L; Fu L; Ma J; Lucas GM; Chawarski M; Ruan Y; Richardson P; Shin K; Chen RY; Sugarman J; Dye BJ; Rose SM; Beauchamp G; Burns DN;
J Acquir Immune Defic Syndr; 2015 Apr; 68(5):554-61. PubMed ID: 25564105
[TBL] [Abstract][Full Text] [Related]
60. Attitudes and availability: A comparison of naloxone dispensing across chain and independent pharmacies in rural and urban areas in Alabama.
Sisson ML; McMahan KB; Chichester KR; Galbraith JW; Cropsey KL
Int J Drug Policy; 2019 Dec; 74():229-235. PubMed ID: 31698165
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
